✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat

AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration.

A doctor utilizing a cloud-based healthcare platform to access patient records.

ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc.’s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company’s commitment to addressing difficult-to-treat tumors.

Despite these clinical milestones, AbbVie Inc.’s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV’s robust long-term performance and future revenue potential as its innovative pipeline matures.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.